Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs
March 14, 2018 07:30 ET
|
Actinium Pharmaceuticals
Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or...
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
March 13, 2018 07:30 ET
|
Actinium Pharmaceuticals
Clinical trial to be conducted by the Medical College of Wisconsin as an investigator initiated trial led by Dr. Sameem Abedin in collaboration with Dr. Ehab Atallah Combination trial expands...
Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period
February 22, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Subscription period expected to end on March 2, 2018 at 5:00 PM ET NEW YORK, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"),...
Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
February 12, 2018 16:15 ET
|
Actinium Pharmaceuticals
• Conference call to be held on Tuesday, February 13th, 2018 at 4:30 PM ET to discuss planned Phase 1 clinical trial with Dr. Ehab Atallah • New trial represents expansion of Actinium’s CD33 program...
Actinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record
February 12, 2018 07:30 ET
|
Actinium Pharmaceuticals
• To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement timing • Actinium’s executive management and...
Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation
February 08, 2018 08:00 ET
|
Actinium Pharmaceuticals
- Mr. Kapur joins Actinium with more than two decades of biopharmaceutical commercial experience at Johnson & Johnson, BAXALTA and Bristol-Myers Squibb - Global leader with deep expertise in...
Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients
February 06, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Actimab-A plus CLAG-M further expands Actinium’s CD33 program and addressable patient population of Actimab-A - Combination aligns with Actinium’s focus on improving bone marrow transplant access...
Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
February 05, 2018 16:15 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO...
Actinium Pharmaceuticals Announces Rights Offering
February 01, 2018 16:05 ET
|
Actinium Pharmaceuticals
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has filed a preliminary prospectus supplement as...
Actinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue
December 27, 2017 09:00 ET
|
Actinium Pharmaceuticals
Actinium expects enhanced awareness of Iomab-B at ASH annual meeting and expanded site activity to enable completion of trial enrollment by end of 2018, in-line with prior forecast NEW YORK, Dec. ...